A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)	Hemic and Lymphatic Diseases, Myeloproliferative Disorders, bone marrow disorder, hematologic disorder, primary myelofibrosis	Recruiting	Phase 3	2026-10-09		NCT07357727

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Novartis Pharmaceuticals	432

19 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
American Oncology Partners PA Center for Cancer and Blood Disorders	Bethesda	United States	2
Columbia University Medical Center New York Presbyterian	New York	United States	3
Florida Cancer Specialist South Reg	Fort Myers	United States	1
Florida Cancer Specialists East	Stuart	United States	2
Florida Cancer Specialists-North	St. Petersburg	United States	4
Franciscan Health Indianapolis	Indianapolis	United States	2
Fred Hutch Cancer Research	Seattle	United States	4
MD Anderson Cancer Center	Houston	United States	589
Miami NS Ins Baptist Health S FL	Miami	United States	2
New York Oncology Hematology P C	Albany	United States	1
SCRI Texas Oncology Northeast Texas	Tyler	United States	1
Summit Medical Group Oncology	Berkeley Heights	United States	1
Texas Oncology PA Dallas Presbyterian Hospital	Dallas	United States	1
The Anderson Family Cancer Institute	Jupiter	United States	1
The Ohio State University Comprehensive Cancer Center	Columbus	United States	5
TxO Austin Midtown	Austin	United States	2
University of Chicago Hospital	Chicago	United States	13
Winship Cancer Institute of Emory University	Atlanta	United States	45
Yale University School Of Medicine	New Haven	United States	22